August 29, 2016
After completing this activity, participants should be able to:
- Describe the clinical progression of inflammatory bowel disease (IBD) and the clinical and economic consequences of undertreatment, including hospital and surgery costs
- Outline unmet patient needs and treatment shortfalls of convention IBD pharmacotherapies
- Evaluate the safety, efficacy, mechanisms-of-action, and pharmacoeconomic profiles of newer IBD treatment modalities
- Develop or augment health plan policies that improve patient access to individualized IBD care
Event details available here.